GLP-1 news & analysis

A plain-English guide to the Medicare GLP-1 Bridge, $50 monthly access, eligibility caveats, and when cash-pay telehealth may still make sense.

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Here is the patient-facing meaning.

The FDA warned telehealth companies about false or misleading compounded GLP-1 marketing. Here are the red flags to avoid.

Cigna’s employee plan change highlights a broader 2026 trend: employers are questioning how to cover expensive obesity drugs.

High-dose semaglutide changes the conversation around maintenance, plateau management, and how patients compare semaglutide with tirzepatide.

Retatrutide results are raising expectations for next-generation obesity medications, but patients still need careful current-treatment decisions.

A recent analysis offered some reassurance around accidental early exposure, but GLP-1 medications are still generally not recommended during pregnancy.

Oral GLP-1 options are becoming mainstream, but injections remain important for many patients. Compare convenience, cost, and expected outcomes.

Use this checklist to evaluate a GLP-1 telehealth program before entering payment or medical information.

After shortages stabilized, compounded GLP-1 marketing faces more scrutiny. This guide explains what patients should ask.

Low prices can be useful, but patients should check dose ceilings, monthly fees, labs, consults, pharmacy sourcing, and cancellation rules.

A patient-focused comparison of semaglutide and tirzepatide for people choosing between price, expected outcomes, and tolerability.

Real-world side effects are often manageable, but dose escalation, dehydration, severe abdominal pain, and persistent vomiting need clinical attention.

Medicare access is changing, but many patients will still need cash-pay or alternative pathways depending on eligibility and timing.

A practical decision guide for comparing GLP-1 telehealth providers by medical review, pricing, pharmacy transparency, support, and disclosures.

Analysis: best wegovy alternatives in 2026 (by cost, effectiveness, insurance)

Analysis: does zepbound cause hair loss? what the data shows (2026)

Analysis: how to get mounjaro for $25 a month (2026 savings card guide)

Analysis: why compounded glp-1 is so much cheaper (and when that's a red flag)

Analysis: legitscript certification, explained for glp-1 patients

Analysis: 503a vs 503b pharmacies: what patients actually need to know

Analysis: novo sues hims, then drops it: the story behind the hims-novo partnership

Analysis: fda compounding rules after the semaglutide shortage ended

Analysis: orforglipron (foundayo) explained: the first oral glp-1 for obesity

Analysis: is oral glp-1 ready to replace injections?

Analysis: glp-1 and alcohol use: what the emerging data shows

Analysis: glp-1 and fertility: conception, washout, and postpartum

Analysis: glp-1 for pcos: off-label use and the evidence base

Analysis: glp-1 and mental health: depression, suicidality, and what fda found

Analysis: glp-1 and bone density: what long-term data shows

Analysis: glp-1 shortages update (may 2026)

Analysis: research peptides vs glp-1: the critical difference

Analysis: tirzepatide vs retatrutide: what the pipeline looks like

Analysis: glp-1 cardiovascular outcomes: select, step-hfpef, and surmount-cv

Analysis: glp-1 and kidney function: the flow trial and beyond

Analysis: glp-1 for mash and fatty liver: where the evidence is

Analysis: why weight comes back after stopping glp-1 — and how to prevent it

Analysis: real patient outcomes on glp-1: what 50 stories show

Analysis: glp-1 in 2025: the year in review

Analysis: wegovy vs ozempic: they're literally the same drug — here's why prices differ

Analysis: glp-1 pricing around the world

Analysis: medicare glp-1 bridge: how to cover the gap before july 2026

Analysis: the compounded pharmacy list every glp-1 patient should know

Analysis: the most important glp-1 research of 2026 (so far)

Analysis: how the glp-1 market is reshaping healthcare stocks